MedPath

TENS Device Shows Promise in Alleviating Long COVID Symptoms

• A new study suggests that Transcutaneous Electrical Nerve Stimulation (TENS) may reduce pain and fatigue associated with long COVID. • Participants using the TENS device reported a 26% reduction in pain and an 8% improvement in walking ability compared to the placebo group. • The TENS device was found to be easy to use, promoting high compliance among participants in the study. • Researchers suggest TENS could potentially benefit individuals with other respiratory diseases or chronic pain conditions, warranting further research.

A Transcutaneous Electrical Nerve Stimulation (TENS) device, commonly used for arthritis and back pain, may offer relief for long COVID symptoms, particularly fatigue and pain, according to a recent study.

Study Details

The study, published in Nature Scientific Reports, involved 25 participants diagnosed with chronic musculoskeletal pain, fatigue, and gait difficulties related to long COVID. Participants were randomly assigned to use either a high-dose TENS device or a placebo device for three to five hours daily over one month. The active TENS device delivers low-wattage electrical currents to stimulate nerves.

Key Findings

Results indicated that participants using the real TENS device experienced a 26% reduction in pain compared to the placebo group. Additionally, an 8% improvement in walking ability was observed. Overall, 71% of participants using the TENS device reported a noticeable health benefit, compared to 61.4% in the placebo group.
Bijan Najafi, research director at UCLA Health's Center for Advanced Surgical & Interventional Technology and co-lead author, noted the device's ease of use and potential for integration into daily activities.

TENS Device and Long COVID

Long COVID is estimated to affect 1 in 13 U.S. adults, with symptoms including fatigue, pain, and muscle weakness. The TENS device offers a non-invasive method to manage these symptoms through nerve stimulation.

Future Research

While the study showed promising results, Najafi emphasized the need for further research to validate these findings, citing the limited sample size. The study was primarily funded by the National Science Foundation, with Neurometrix Inc. providing the Quell TENS devices.

Potential Applications

Researchers suggest that TENS may have broader applications for managing similar symptoms in other conditions, such as respiratory diseases, post-ICU weakness, fibromyalgia, and chemotherapy-related side effects. Further studies are needed to explore these potential uses.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tonix Pharmaceuticals' TNX-102 SL Shows Promise in Fibromyalgia Treatment

Tonix Pharmaceuticals presented Phase 3 RESILIENT study data, revealing TNX-102 SL significantly reduced fibromyalgia pain versus placebo.
The study met all six key secondary endpoints, including improved sleep quality, reduced fatigue, and enhanced overall function in patients.

Tonix Pharmaceuticals' TNX-102 SL Awaits FDA Decision for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, a non-opioid analgesic, has been assigned an FDA PDUFA goal date of August 15, 2025, for fibromyalgia treatment, potentially offering a new option for millions.
TNX-102 SL demonstrated significant pain reduction and improved sleep quality in Phase 3 trials, addressing key fibromyalgia symptoms with a well-tolerated safety profile.

Asunercept Shows Promise in Reducing Mortality and Accelerating Recovery in Severe COVID-19

A Phase 2 clinical trial reveals that asunercept, a FasL inhibitor, significantly accelerates recovery in patients with severe COVID-19, reducing the average recovery time from 13 to 8 days.
The study also indicates a roughly 20% reduction in mortality among patients treated with asunercept at 100mg and 400mg doses compared to the standard of care.

Acupuncture Shows Promise in Reducing Acute Musculoskeletal Pain in the Emergency Department

A clinical trial at Duke University Hospital found that acupuncture, when added to standard care, significantly reduced acute musculoskeletal pain in emergency department patients.
The study demonstrated the feasibility of integrating acupuncture into a busy emergency department setting, offering an alternative or adjunct to traditional medication-based pain management.

Epineuron's PeriPulse System Receives Health Canada Approval for Nerve Regeneration

Epineuron has received Health Canada approval for its PeriPulse™ system, designed to enhance nerve regeneration in patients with severe nerve injuries and chronic neurological conditions.
The PeriPulse™ system features an advanced shapeable electrode and a patient-wearable component, facilitating quick deployment and electrical stimulation therapy in the recovery room.

Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Relief

Medtronic's Inceptiv, a spinal cord stimulator, has gained FDA approval for managing chronic pain by automatically adjusting stimulation based on biological signals.
The device is implanted and works by sensing signals and blocking pain signals before they reach the brain, offering a potential alternative to traditional pain management.

RAPID_REVIVE Trial to Evaluate Vidofludimus Calcium for Post-COVID Syndrome

The RAPID_REVIVE study, led by Frankfurt University Hospital, is a phase 2 trial investigating treatments for post-COVID syndrome (PCS).
The trial will assess vidofludimus calcium (IMU-838), a drug that activates Nurr1 and inhibits DHODH, potentially reducing inflammation and viral infection.

rTMS Shows Promise for Chronic Neuropathic Pain Relief in UCSF Study

A UCSF study is evaluating repetitive transcranial magnetic stimulation (rTMS) as a treatment for chronic neuropathic pain, which affects a significant portion of the population.
The research focuses on high-frequency rTMS applied to the motor cortex (M1), a region previously shown to benefit chronic neuropathic pain, to modulate brain activity.

Tonix Pharmaceuticals' Tonmya™ Receives Conditional FDA Acceptance for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, conditionally named Tonmya™, has received FDA acceptance as a trade name for fibromyalgia management.
Two positive Phase 3 trials demonstrated Tonmya's potential as a novel, first-line treatment option for fibromyalgia, affecting millions in the U.S.

Therapeutic Trials for Long COVID-19: A Call to Action

The article discusses the ongoing challenges and research efforts in understanding and treating Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC). It highlights the need for therapeutic trials to address the persistent symptoms affecting a significant number of individuals post-acute SARS-CoV-2 infection. The National Institutes of Health's RECOVER initiative is mentioned as a key effort in this area, focusing on understanding the biological mechanisms behind Long COVID and exploring potential treatments.

Reference News

[1]
Nerve Stimulation Device Might Ease Long COVID Symptoms
drugs.com · Apr 17, 2025

A study published in Nature Scientific Reports suggests that a wearable Transcutaneous Electrical Nerve Stimulation (TEN...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy